Inside the Norstella Panel: The Engine Behind Smarter Access Decisions
The Norstella Panel puts you in the room with the people who decide. Active P&T leaders. Payer and PBM decision makers. Provider and IDN influencers. The voices shaping coverage in real time. As the industry’s leading partner in access, Norstella delivers reach others simply can’t match. Download the infographic to see the scale, specialization, and […]
The Growing Strategic Influence of Market Access
Market access professionals tell us that their role is becoming increasingly influential amid a turbulent policy environment and intense competitive landscape. This was one of the clearest results from a survey commissioned by MMIT and The Dedham Group, which we explored in a recent white paper called Working Backwards: Patient access strategy is now guiding […]
The R&D Implications of Market Access Complexity
Our latest research strongly suggests that a highly dynamic market access situation in the US is feeding back into upstream decisions around R&D strategy. We explored this topic in detail in a recent white paper called Working Backwards: Patient access strategy is now guiding R&D. This article briefly summarizes the first half of the report. […]
Working Backwards: Patient Access Strategy is Now Guiding R&D
Drawing from research from across the breadth of Norstella, this white paper lays out the argument for the increasing strategic influence of patient access. The pricing and reimbursement landscape in the US remains volatile as the various stakeholders react to new policies and the increasing complexity of new drug launches. This is creating the conditions […]
The Greatest Opportunities to Enhance Drug Development in 2025
The pharma industry continues to persevere through talent shortages, supply chain disruptions, data challenges, and many more obstacles that are making it increasingly difficult to get life-saving treatments to patients. However, the thirst for innovation and drive to make a difference for patients around the world is what keeps this sector going. As we start […]
Addressing Cost Barriers and Enhancing Medicare Access Strategies to Improve Commercialization Strategy
A pharmaceutical manufacturer sought to enhance their product’s commercialization strategy by analyzing patient profiles, the market access landscape, and competitive dynamics. The client was aiming to: Refine its market access strategy to address affordability challenges Identify unmet needs in the treatment landscape for recurrent infections
Innovation Trends from R&D to Market Access
2024 has been an incredibly busy year for Norstella as its constituent organizations – Citeline, Evaluate, MMIT, Panalgo, and the Dedham Group – have continued to support the biopharma ecosystem in bringing new therapies to patients. Throughout the course of the year, we have also shared our latest views on the issues that are most […]
Redefining Patient Access Strategy
Patient access continues to be a major hurdle in the US pharma industry, impacting the speed of drug development and therefore the delivery of life-saving treatments to patients. To assess the current state of patient access, Norstella’s Managed Markets Insight & Technology (MMIT) surveyed over 300 industry professionals on major trends and challenges in pharma […]
Putting the Patient First: Advancing Biopharma Innovation and Industry Transformation
Norstella is driven by its mission: Helping patients gain access to life-saving therapies by transforming the drug development journey. Norstella is working to fulfill this mission in a challenging landscape for pharmaceutical, medtech, and clinical research organizations. With this as the context, Norstella recently held a recent roundtable discussion in London featuring several members of […]
5 Barriers to Access for Sickle Cell Disease Gene Therapies
Sickle cell disease (SCD) is a genetic blood disorder that affects the lives of 100,000 Americans1. SCD causes abnormal hemoglobin molecules in the red blood cells, resulting in cells forming in a crescent or sickle shape, which can block blood vessels and cause pain, organ damage, and other complications. This cellular-level disfunction is addressable with […]
